KORRO BIO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 51.26 USD | -2.86% |
|
-6.60% | +6.95% |
| May. 15 | HC Wainwright Adjusts Korro Bio's Price Target to $100 From $115, Keeps Buy Rating | MT |
| May. 14 | Korro Bio Q1 Net Loss Shrinks; Kemi Olugemo Appointed as Chief Medical Officer | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 475M |
|---|---|---|---|---|---|
| Net income 2024 * | -81M | Net income 2025 * | -92M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-5.32
x | P/E ratio 2025 * |
-5.43
x | Employees | 102 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.49% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | -2.86% | ||
| 1 week | -6.60% | ||
| Current month | -9.74% | ||
| 1 month | -30.13% | ||
| 3 months | -2.16% | ||
| 6 months | +25.64% | ||
| Current year | +6.95% |
1 week
49.15
52.98
1 month
49.1572.96
Current year
38.7597.91
1 year
14.0097.91
3 years
14.0097.91
5 years
14.0097.91
10 years
14.0097.91
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-16 | 51.26 | -2.86% | 37,317 |
| 24-05-15 | 52.77 | +5.43% | 34,955 |
| 24-05-14 | 50.05 | -0.38% | 27,027 |
| 24-05-13 | 50.24 | -1.49% | 50,951 |
| 24-05-10 | 51 | -7.07% | 25,832 |
Delayed Quote Nasdaq, May 16, 2024 at 04:00 pm EDT
More quotes
Korro Bio, Inc. is a biopharmaceutical company. The Company discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The Company is generating a portfolio of differentiated programs that are designed to harness the bodyâs natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Its Oligonucleotide Promoted Editing of RNA (OPERA) is a foundational platform for RNA editing, which is designed to edit RNA in vivo by delivering an oligonucleotide guide that can target specific RNA sequences. The Companyâs first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD), that has the potential to be disease-modifying and provide a differentiated therapeutic option.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
51.26
USD
Average target price
126.2
USD
Spread / Average Target
+146.29%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +6.95% | 475M | |
| +33.37% | 50.85B | |
| +1.55% | 42.82B | |
| +48.66% | 42.03B | |
| -4.22% | 29.55B | |
| +11.57% | 26.11B | |
| -21.00% | 19.13B | |
| +7.36% | 13.05B | |
| +28.30% | 12.16B | |
| +23.80% | 12.08B |
- Stock Market
- Equities
- KRRO Stock
